首页 > 最新文献

ACS Medicinal Chemistry Letters最新文献

英文 中文
Microbiota-induced alteration of kynurenine metabolism in macrophages drives formation of creeping fat in Crohn’s disease 微生物诱导的巨噬细胞犬尿氨酸代谢改变促使克罗恩病中爬行脂肪的形成
IF 30.3 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-13 DOI: 10.1016/j.chom.2024.10.008
Jinjie Wu, Wanyi Zeng, Hongyu Xie, Mujia Cao, Jingyi Yang, Yanchun Xie, Zhanhao Luo, Zongjin Zhang, Haoyang Xu, Weidong Huang, Tingyue Zhou, Jinyu Tan, Xiaomin Wu, Zihuan Yang, Shu Zhu, Ren Mao, Zhen He, Ping Lan
Hyperplasia of mesenteric tissues in Crohn’s disease, called creeping fat (CrF), is associated with surgical recurrence. Although microbiota translocation and colonization have been found in CrF, convincing mouse phenotypes and the underlying mechanisms of CrF formation remain unclear. Utilizing single-nucleus RNA (snRNA) sequencing of CrF and different mouse models, we demonstrate that the commensal Achromobacter pulmonis induces mesenteric adipogenesis through macrophage alteration. Targeted metabolome analysis reveals that L-kynurenine is the most enriched metabolite in CrF. Upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) enhances kynurenine metabolism and drives mesenteric adipogenesis. Leveraging single-cell RNA (scRNA) sequencing of mouse mesenteric tissues and macrophage-specific IDO1 knockout mice, we verify the role of macrophage-sourced L-kynurenine in mesenteric adipogenesis. Mechanistically, L-kynurenine-induced adipogenesis is mediated by the aryl hydrocarbon receptors in adipocytes. Administration of an IDO1 inhibitor or bacteria engineered to degrade L-kynurenine alleviates mesenteric adipogenesis in mice. Collectively, our study demonstrates that microbiota-induced modulation of macrophage metabolism potentiates CrF formation.
克罗恩病肠系膜组织的增生被称为爬行脂肪(CrF),与手术复发有关。虽然在 CrF 中发现了微生物群易位和定植,但令人信服的小鼠表型和 CrF 形成的潜在机制仍不清楚。利用对 CrF 和不同小鼠模型的单核 RNA(snRNA)测序,我们证明了肠道共生菌 Achromobacter pulmonis 可通过改变巨噬细胞诱导肠系膜脂肪生成。靶向代谢组分析表明,L-犬尿氨酸是 CrF 中含量最高的代谢物。吲哚胺 2,3-二氧合酶 1(IDO1)的上调增强了犬尿氨酸的代谢,并推动了肠系膜脂肪的生成。通过对小鼠肠系膜组织和巨噬细胞特异性 IDO1 基因敲除小鼠进行单细胞 RNA(scRNA)测序,我们验证了巨噬细胞来源的 L-犬尿氨酸在肠系膜脂肪生成中的作用。从机理上讲,L-犬尿氨酸诱导的脂肪生成是由脂肪细胞中的芳基烃受体介导的。服用 IDO1 抑制剂或降解 L-犬尿氨酸的细菌可减轻小鼠肠系膜脂肪的生成。总之,我们的研究表明,微生物诱导的巨噬细胞新陈代谢调节可促进 CrF 的形成。
{"title":"Microbiota-induced alteration of kynurenine metabolism in macrophages drives formation of creeping fat in Crohn’s disease","authors":"Jinjie Wu, Wanyi Zeng, Hongyu Xie, Mujia Cao, Jingyi Yang, Yanchun Xie, Zhanhao Luo, Zongjin Zhang, Haoyang Xu, Weidong Huang, Tingyue Zhou, Jinyu Tan, Xiaomin Wu, Zihuan Yang, Shu Zhu, Ren Mao, Zhen He, Ping Lan","doi":"10.1016/j.chom.2024.10.008","DOIUrl":"https://doi.org/10.1016/j.chom.2024.10.008","url":null,"abstract":"Hyperplasia of mesenteric tissues in Crohn’s disease, called creeping fat (CrF), is associated with surgical recurrence. Although microbiota translocation and colonization have been found in CrF, convincing mouse phenotypes and the underlying mechanisms of CrF formation remain unclear. Utilizing single-nucleus RNA (snRNA) sequencing of CrF and different mouse models, we demonstrate that the commensal <em>Achromobacter pulmonis</em> induces mesenteric adipogenesis through macrophage alteration. Targeted metabolome analysis reveals that L-kynurenine is the most enriched metabolite in CrF. Upregulation of indoleamine 2,3-dioxygenase 1 (IDO1) enhances kynurenine metabolism and drives mesenteric adipogenesis. Leveraging single-cell RNA (scRNA) sequencing of mouse mesenteric tissues and macrophage-specific IDO1 knockout mice, we verify the role of macrophage-sourced L-kynurenine in mesenteric adipogenesis. Mechanistically, L-kynurenine-induced adipogenesis is mediated by the aryl hydrocarbon receptors in adipocytes. Administration of an IDO1 inhibitor or bacteria engineered to degrade L-kynurenine alleviates mesenteric adipogenesis in mice. Collectively, our study demonstrates that microbiota-induced modulation of macrophage metabolism potentiates CrF formation.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"7 1","pages":""},"PeriodicalIF":30.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beta-carbolines suppress vaginal inflammation β-碳酸氢盐抑制阴道炎症
IF 30.3 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-13 DOI: 10.1016/j.chom.2024.10.005
Cancan Qi, Ri-hua Xie, Yan He, Muxuan Chen
Vaginal lactobacilli are key regulators of host inflammation, yet the mechanisms remain understudied. In this issue of Cell Host & Microbe, Glick et al. identify a family of beta-carbolines as anti-inflammatory effectors produced by vaginal Lactobacillus species, highlighting their potential as therapeutics for vaginal inflammatory disorders.
阴道乳酸杆菌是宿主炎症的关键调节因子,但其作用机制仍未得到充分研究。在本期《细胞-宿主-微生物》(Cell Host & Microbe)杂志上,Glick 等人发现了阴道乳酸杆菌产生的抗炎效应物--β-carbolines 家族,并强调了它们作为阴道炎症性疾病治疗药物的潜力。
{"title":"Beta-carbolines suppress vaginal inflammation","authors":"Cancan Qi, Ri-hua Xie, Yan He, Muxuan Chen","doi":"10.1016/j.chom.2024.10.005","DOIUrl":"https://doi.org/10.1016/j.chom.2024.10.005","url":null,"abstract":"Vaginal lactobacilli are key regulators of host inflammation, yet the mechanisms remain understudied. In this issue of <em>Cell Host &amp; Microbe</em>, Glick et al. identify a family of beta-carbolines as anti-inflammatory effectors produced by vaginal <em>Lactobacillus</em> species, highlighting their potential as therapeutics for vaginal inflammatory disorders.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"95 1","pages":""},"PeriodicalIF":30.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The brightest multi-colour phonon lasers 最亮的多色声子激光器
3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-13 DOI: 10.1038/s41377-024-01648-2
Mishkat Bhattacharya

A new device applies a single-colour electronic injection to create the brightest multi-colour phonon laser, with ten times more power and much narrower linewidth than others.

一种新设备利用单色电子注入技术制造出最明亮的多色声子激光器,其功率是其他设备的十倍,线宽也窄得多。
{"title":"The brightest multi-colour phonon lasers","authors":"Mishkat Bhattacharya","doi":"10.1038/s41377-024-01648-2","DOIUrl":"https://doi.org/10.1038/s41377-024-01648-2","url":null,"abstract":"<p>A new device applies a single-colour electronic injection to create the brightest multi-colour phonon laser, with ten times more power and much narrower linewidth than others.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"95 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142601018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. 贝利木单抗对系统性红斑狼疮疾病调节作用的分子基础以及早期反应的分子预测因素:血液转录组分析与先天性免疫和DNA损伤反应途径有关。
IF 20.3 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-13 DOI: 10.1136/ard-2024-226051
Georgia-Savina Moysidou, Panagiotis Garantziotis, George Sentis, Dimitra Nikoleri, Nikolaos Malissovas, Myrto Nikoloudaki, Eirini-Maria Stergioti, Styliani Polia, Nikolaos Paschalidis, Anastasia Filia, Maria Grigoriou, Dionysis Nikolopoulos, Noemin Kapsala, Spyridon Katechis, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas

Objectives: Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study.

Methods: RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of belimumab treatment (n=45 paired samples). Clinical response was determined according to the SLE Responder Index (SRI)-4 and Lupus Low Disease Activity State (LLDAS). Weighted correlation network analysis (WGCNA) was used to uncover gene module trait associations. Reversibility of SLE susceptibility and severity gene signatures was assessed. Machine learning was used to build models predictive of response.

Results: Belimumab induced widespread transcriptome changes with downregulation of pathways related to B cells, type I/II interferon, IL-6/STAT3 and neutrophil activation. These effects were more pronounced among patients with LLDAS+ compared with to SRI-4+/LLDAS- response, with amelioration of the SLE 'susceptibility' signature observed in the former group. Unsupervised analysis unveiled gene modules enriched in neutrophil degranulation, type I interferon signalling and cytokine production to correlate positively with response at 6 months. Using neural networks, a set of 50 genes (including CCL4L2, CARD10, MMP15 and KLRC2) predicted response to belimumab with a cross-validated 84% specificity (test set). Lack of response was linked to perturbations of the cell cycle checkpoints, PI3K/Akt/mammalian target of rapamycin and TGF-beta signalling pathways.

Conclusion: Belimumab treatment ameliorates multiple innate and adaptive immunity dysregulations of SLE and may reverse the disease signature, consistent with the drug effects on reducing activity and preventing flares. Fingerprints of innate immunity correlate with robust improvement whereas DNA damage response with less responsive disease to BAFF inhibition.

目的:贝利木单抗是一种治疗系统性红斑狼疮(SLE)的改良药物,但其作用的分子基础以及预测早期临床反应的能力仍有待探索。为了解决这些问题,我们进行了一项纵向、深入的血液转录组研究:方法:我们对活动性系统性红斑狼疮患者基线和贝利木单抗治疗6个月后的血液进行了RNA测序(45份配对样本)。根据系统性红斑狼疮应答者指数(SRI)-4和狼疮低疾病活动状态(LLDAS)确定临床应答。加权相关网络分析(WGCNA)用于揭示基因模块性状关联。评估了系统性红斑狼疮易感性和严重性基因特征的可逆性。机器学习用于建立预测反应的模型:结果:贝利姆单抗诱导了广泛的转录组变化,下调了与B细胞、I/II型干扰素、IL-6/STAT3和中性粒细胞活化相关的通路。与SRI-4+/LLDAS-反应相比,这些影响在LLDAS+患者中更为明显,前者的系统性红斑狼疮 "易感性 "特征有所改善。无监督分析揭示了富含中性粒细胞脱颗粒、I型干扰素信号传导和细胞因子产生的基因模块与6个月时的反应呈正相关。利用神经网络,一组50个基因(包括CCL4L2、CARD10、MMP15和KLRC2)预测了对贝利木单抗的反应,交叉验证的特异性为84%(测试集)。缺乏反应与细胞周期检查点、PI3K/Akt/哺乳动物雷帕霉素靶点和TGF-beta信号通路的扰动有关:结论:贝利姆单抗治疗可改善系统性红斑狼疮的多种先天性和适应性免疫失调,并可逆转疾病特征,这与药物降低活动性和预防复发的效果一致。先天性免疫指纹与疾病的显著改善相关,而DNA损伤反应则与疾病对BAFF抑制的反应较弱相关。
{"title":"Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.","authors":"Georgia-Savina Moysidou, Panagiotis Garantziotis, George Sentis, Dimitra Nikoleri, Nikolaos Malissovas, Myrto Nikoloudaki, Eirini-Maria Stergioti, Styliani Polia, Nikolaos Paschalidis, Anastasia Filia, Maria Grigoriou, Dionysis Nikolopoulos, Noemin Kapsala, Spyridon Katechis, Antonis Fanouriakis, George Bertsias, Dimitrios T Boumpas","doi":"10.1136/ard-2024-226051","DOIUrl":"https://doi.org/10.1136/ard-2024-226051","url":null,"abstract":"<p><strong>Objectives: </strong>Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study.</p><p><strong>Methods: </strong>RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of belimumab treatment (n=45 paired samples). Clinical response was determined according to the SLE Responder Index (SRI)-4 and Lupus Low Disease Activity State (LLDAS). Weighted correlation network analysis (WGCNA) was used to uncover gene module trait associations. Reversibility of SLE susceptibility and severity gene signatures was assessed. Machine learning was used to build models predictive of response.</p><p><strong>Results: </strong>Belimumab induced widespread transcriptome changes with downregulation of pathways related to B cells, type I/II interferon, IL-6/STAT3 and neutrophil activation. These effects were more pronounced among patients with LLDAS+ compared with to SRI-4+/LLDAS- response, with amelioration of the SLE 'susceptibility' signature observed in the former group. Unsupervised analysis unveiled gene modules enriched in neutrophil degranulation, type I interferon signalling and cytokine production to correlate positively with response at 6 months. Using neural networks, a set of 50 genes (including <i>CCL4L2, CARD10, MMP1</i>5 and <i>KLRC2</i>) predicted response to belimumab with a cross-validated 84% specificity (test set). Lack of response was linked to perturbations of the cell cycle checkpoints, PI3K/Akt/mammalian target of rapamycin and TGF-beta signalling pathways.</p><p><strong>Conclusion: </strong>Belimumab treatment ameliorates multiple innate and adaptive immunity dysregulations of SLE and may reverse the disease signature, consistent with the drug effects on reducing activity and preventing flares. Fingerprints of innate immunity correlate with robust improvement whereas DNA damage response with less responsive disease to BAFF inhibition.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":" ","pages":""},"PeriodicalIF":20.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Innovative CQD detector for broadband multispectral imaging 用于宽带多光谱成像的创新型 CQD 探测器
3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-12 DOI: 10.1038/s41377-024-01621-z
Shengli Sun, Yaran Li, Fansheng Chen

Nature Photonics 18, 1147–1154 (2024)

自然-光子学》18 卷,1147-1154(2024 年)
{"title":"Innovative CQD detector for broadband multispectral imaging","authors":"Shengli Sun, Yaran Li, Fansheng Chen","doi":"10.1038/s41377-024-01621-z","DOIUrl":"https://doi.org/10.1038/s41377-024-01621-z","url":null,"abstract":"<p><i>Nature Photonics</i> <b>18</b>, 1147–1154 (2024)</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bessel beam optical coherence microscopy enables multiscale assessment of cerebrovascular network morphology and function 贝塞尔光束光学相干显微镜可对脑血管网络的形态和功能进行多尺度评估
3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-11 DOI: 10.1038/s41377-024-01649-1
Lukas Glandorf, Bastian Wittmann, Jeanne Droux, Chaim Glück, Bruno Weber, Susanne Wegener, Mohamad El Amki, Rainer Leitgeb, Bjoern Menze, Daniel Razansky

Understanding the morphology and function of large-scale cerebrovascular networks is crucial for studying brain health and disease. However, reconciling the demands for imaging on a broad scale with the precision of high-resolution volumetric microscopy has been a persistent challenge. In this study, we introduce Bessel beam optical coherence microscopy with an extended focus to capture the full cortical vascular hierarchy in mice over 1000 × 1000 × 360 μm3 field-of-view at capillary level resolution. The post-processing pipeline leverages a supervised deep learning approach for precise 3D segmentation of high-resolution angiograms, hence permitting reliable examination of microvascular structures at multiple spatial scales. Coupled with high-sensitivity Doppler optical coherence tomography, our method enables the computation of both axial and transverse blood velocity components as well as vessel-specific blood flow direction, facilitating a detailed assessment of morpho-functional characteristics across all vessel dimensions. Through graph-based analysis, we deliver insights into vascular connectivity, all the way from individual capillaries to broader network interactions, a task traditionally challenging for in vivo studies. The new imaging and analysis framework extends the frontiers of research into cerebrovascular function and neurovascular pathologies.

了解大规模脑血管网络的形态和功能对于研究大脑健康和疾病至关重要。然而,如何协调大尺度成像需求与高分辨率容积显微镜的精确性一直是个难题。在这项研究中,我们引入了具有扩展焦点的贝塞尔光束光学相干显微镜,以毛细管级分辨率捕捉小鼠1000 × 1000 × 360 μm3视场的完整皮层血管层次。后处理管道利用监督深度学习方法对高分辨率血管图进行精确的三维分割,从而在多个空间尺度上对微血管结构进行可靠的检查。结合高灵敏度多普勒光学相干断层扫描,我们的方法能够计算轴向和横向血流速度成分以及特定血管的血流方向,从而有助于详细评估所有血管维度的形态功能特征。通过基于图的分析,我们可以深入了解血管的连通性,从单个毛细血管到更广泛的网络互动,这是一项传统上对体内研究具有挑战性的任务。新的成像和分析框架拓展了脑血管功能和神经血管病理学的研究领域。
{"title":"Bessel beam optical coherence microscopy enables multiscale assessment of cerebrovascular network morphology and function","authors":"Lukas Glandorf, Bastian Wittmann, Jeanne Droux, Chaim Glück, Bruno Weber, Susanne Wegener, Mohamad El Amki, Rainer Leitgeb, Bjoern Menze, Daniel Razansky","doi":"10.1038/s41377-024-01649-1","DOIUrl":"https://doi.org/10.1038/s41377-024-01649-1","url":null,"abstract":"<p>Understanding the morphology and function of large-scale cerebrovascular networks is crucial for studying brain health and disease. However, reconciling the demands for imaging on a broad scale with the precision of high-resolution volumetric microscopy has been a persistent challenge. In this study, we introduce Bessel beam optical coherence microscopy with an extended focus to capture the full cortical vascular hierarchy in mice over 1000 × 1000 × 360 μm<sup>3</sup> field-of-view at capillary level resolution. The post-processing pipeline leverages a supervised deep learning approach for precise 3D segmentation of high-resolution angiograms, hence permitting reliable examination of microvascular structures at multiple spatial scales. Coupled with high-sensitivity Doppler optical coherence tomography, our method enables the computation of both axial and transverse blood velocity components as well as vessel-specific blood flow direction, facilitating a detailed assessment of morpho-functional characteristics across all vessel dimensions. Through graph-based analysis, we deliver insights into vascular connectivity, all the way from individual capillaries to broader network interactions, a task traditionally challenging for in vivo studies. The new imaging and analysis framework extends the frontiers of research into cerebrovascular function and neurovascular pathologies.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epileptiform Electrographic Patterns After Cardiac Arrest 心脏骤停后的癫痫样电图模式
IF 29 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-11 DOI: 10.1001/jamaneurol.2024.3831
Andrea O. Rossetti, Sarah Benghanem
This Viewpoint challenges conventional clinical practice that eschews pharmacological intervention for comatose patients with epileptiform abnormalities after cardiac arrest using evidence from the Treatment of Electroencephalographic Status Epilepticus after Cardiopulmonary Resuscitation (TELSTAR) trial.
本视点利用心肺复苏术后脑电图癫痫状态治疗(TELSTAR)试验的证据,对心脏骤停后出现癫痫样异常的昏迷患者放弃药物干预的传统临床实践提出了质疑。
{"title":"Epileptiform Electrographic Patterns After Cardiac Arrest","authors":"Andrea O. Rossetti, Sarah Benghanem","doi":"10.1001/jamaneurol.2024.3831","DOIUrl":"https://doi.org/10.1001/jamaneurol.2024.3831","url":null,"abstract":"This Viewpoint challenges conventional clinical practice that eschews pharmacological intervention for comatose patients with epileptiform abnormalities after cardiac arrest using evidence from the Treatment of Electroencephalographic Status Epilepticus after Cardiopulmonary Resuscitation (TELSTAR) trial.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"95 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Event-Enhanced Snapshot Compressive Videography at 10K FPS 以 10K FPS 的速度进行事件增强快照压缩摄像
IF 23.6 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-11 DOI: 10.1109/tpami.2024.3496788
Bo Zhang, Jinli Suo, Qionghai Dai
{"title":"Event-Enhanced Snapshot Compressive Videography at 10K FPS","authors":"Bo Zhang, Jinli Suo, Qionghai Dai","doi":"10.1109/tpami.2024.3496788","DOIUrl":"https://doi.org/10.1109/tpami.2024.3496788","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"11 1","pages":""},"PeriodicalIF":23.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hi-SAM: Marrying Segment Anything Model for Hierarchical Text Segmentation Hi-SAM:为分层文本分段建立分段模型
IF 23.6 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-11 DOI: 10.1109/tpami.2024.3495831
Maoyuan Ye, Jing Zhang, Juhua Liu, Chenyu Liu, Baocai Yin, Cong Liu, Bo Du, Dacheng Tao
{"title":"Hi-SAM: Marrying Segment Anything Model for Hierarchical Text Segmentation","authors":"Maoyuan Ye, Jing Zhang, Juhua Liu, Chenyu Liu, Baocai Yin, Cong Liu, Bo Du, Dacheng Tao","doi":"10.1109/tpami.2024.3495831","DOIUrl":"https://doi.org/10.1109/tpami.2024.3495831","url":null,"abstract":"","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"33 1","pages":""},"PeriodicalIF":23.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty Trajectories Preceding Dementia in the US and UK 美国和英国老年痴呆症前的虚弱轨迹
IF 29 3区 医学 Q2 CHEMISTRY, MEDICINAL Pub Date : 2024-11-11 DOI: 10.1001/jamaneurol.2024.3774
David D. Ward, Jonny P. Flint, Thomas J. Littlejohns, Isabelle F. Foote, Marco Canevelli, Lindsay M. K. Wallace, Emily H. Gordon, David J. Llewellyn, Janice M. Ranson, Ruth E. Hubbard, Kenneth Rockwood, Erwin Stolz
ImportanceAn accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature of the relationship between frailty and dementia is not well understood.ObjectiveTo clarify the temporal relationship between frailty and incident dementia by investigating frailty trajectories in the years preceding dementia onset.Design, Setting, and ParticipantsParticipant data came from 4 prospective cohort studies: the English Longitudinal Study of Ageing, the Health and Retirement Study, the Rush Memory and Aging Project, and the National Alzheimer Coordinating Center. Data were collected between 1997 and 2024 and were analyzed from July 2023 to August 2024. The settings were retirement communities, national-level surveys, and a multiclinic-based cohort. Included individuals were 60 years or older and without cognitive impairment at baseline. Included individuals also had data on age, sex, education level, and ethnicity and a frailty index score calculated at baseline.ExposureFrailty was the main exposure, with participants’ degrees of frailty quantified using retrospectively calculated frailty index scores.Main Outcomes and MeasuresIncident all-cause dementia ascertained through physician-derived diagnoses, self- and informant-report, and estimated classifications based on combinations of cognitive tests.ResultsThe participant number before exclusions was 87 737. After exclusions, data from 29 849 participants (mean [SD] age, 71.6 [7.7] years; 18 369 female [62%]; 257 963 person-years of follow-up; 3154 cases of incident dementia) were analyzed. Bayesian generalized linear mixed regression models revealed accelerations in frailty trajectories 4 to 9 years before incident dementia. Overall, frailty was positively associated with dementia risk (adjusted hazard ratios [aHRs] ranged from 1.18; 95% CI, 1.13-1.24 to 1.73; 95% CI, 1.57-1.92). This association held among participants whose time between frailty measurement and incident dementia exceeded the identified acceleration period (aHRs ranged from 1.18; 95% CI, 1.12-1.23 to 1.43; 95% CI, 1.14-1.80).Conclusions and RelevanceThese findings suggest that frailty measurements may be used to identify high-risk population groups for preferential enrolment into clinical trials for dementia prevention and treatment. Frailty itself may represent a useful upstream target for behavioral and societal approaches to dementia prevention.
重要性一个可用于衡量生物年龄和痴呆症风险的指标对于推进痴呆症预防和治疗策略至关重要。设计、环境和参与者参与者的数据来自 4 项前瞻性队列研究:英国老龄化纵向研究、健康与退休研究、拉什记忆与老龄化项目和国家阿尔茨海默氏症协调中心。数据收集时间为 1997 年至 2024 年,分析时间为 2023 年 7 月至 2024 年 8 月。数据收集的环境包括退休社区、国家级调查和多临床队列。研究对象年龄在 60 岁或以上,基线时无认知障碍。主要结果和测量通过医生诊断、自我报告和信息报告以及基于认知测试组合的估计分类来确定所有原因的痴呆事件。结果排除前的参与者人数为 87 737 人。排除后,分析了 29 849 名参与者的数据(平均 [SD] 年龄 71.6 [7.7] 岁;18 369 名女性 [62%];随访 257 963 人年;3154 例痴呆症患者)。贝叶斯广义线性混合回归模型显示,在痴呆症发病前 4 到 9 年,虚弱轨迹会加速发展。总体而言,虚弱与痴呆症风险呈正相关(调整后危险比 [aHRs] 从 1.18; 95% CI, 1.13-1.24 到 1.73; 95% CI, 1.57-1.92)。这些研究结果表明,虚弱程度测量可用于识别高风险人群,使其优先加入痴呆症预防和治疗的临床试验。虚弱本身就可能是预防痴呆症的行为和社会方法的一个有用的上游目标。
{"title":"Frailty Trajectories Preceding Dementia in the US and UK","authors":"David D. Ward, Jonny P. Flint, Thomas J. Littlejohns, Isabelle F. Foote, Marco Canevelli, Lindsay M. K. Wallace, Emily H. Gordon, David J. Llewellyn, Janice M. Ranson, Ruth E. Hubbard, Kenneth Rockwood, Erwin Stolz","doi":"10.1001/jamaneurol.2024.3774","DOIUrl":"https://doi.org/10.1001/jamaneurol.2024.3774","url":null,"abstract":"ImportanceAn accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature of the relationship between frailty and dementia is not well understood.ObjectiveTo clarify the temporal relationship between frailty and incident dementia by investigating frailty trajectories in the years preceding dementia onset.Design, Setting, and ParticipantsParticipant data came from 4 prospective cohort studies: the English Longitudinal Study of Ageing, the Health and Retirement Study, the Rush Memory and Aging Project, and the National Alzheimer Coordinating Center. Data were collected between 1997 and 2024 and were analyzed from July 2023 to August 2024. The settings were retirement communities, national-level surveys, and a multiclinic-based cohort. Included individuals were 60 years or older and without cognitive impairment at baseline. Included individuals also had data on age, sex, education level, and ethnicity and a frailty index score calculated at baseline.ExposureFrailty was the main exposure, with participants’ degrees of frailty quantified using retrospectively calculated frailty index scores.Main Outcomes and MeasuresIncident all-cause dementia ascertained through physician-derived diagnoses, self- and informant-report, and estimated classifications based on combinations of cognitive tests.ResultsThe participant number before exclusions was 87 737. After exclusions, data from 29 849 participants (mean [SD] age, 71.6 [7.7] years; 18 369 female [62%]; 257 963 person-years of follow-up; 3154 cases of incident dementia) were analyzed. Bayesian generalized linear mixed regression models revealed accelerations in frailty trajectories 4 to 9 years before incident dementia. Overall, frailty was positively associated with dementia risk (adjusted hazard ratios [aHRs] ranged from 1.18; 95% CI, 1.13-1.24 to 1.73; 95% CI, 1.57-1.92). This association held among participants whose time between frailty measurement and incident dementia exceeded the identified acceleration period (aHRs ranged from 1.18; 95% CI, 1.12-1.23 to 1.43; 95% CI, 1.14-1.80).Conclusions and RelevanceThese findings suggest that frailty measurements may be used to identify high-risk population groups for preferential enrolment into clinical trials for dementia prevention and treatment. Frailty itself may represent a useful upstream target for behavioral and societal approaches to dementia prevention.","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"154 1","pages":""},"PeriodicalIF":29.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ACS Medicinal Chemistry Letters
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1